Teotard capsules modified-release

Nchi: Armenia

Lugha: Kiingereza

Chanzo: Դեղերի և բժշկական տեխնոլոգիաների փորձագիտական կենտրոնի գործունեության Հայաստանի Հանրապետությունում

Viambatanisho vya kazi:

theophylline

Inapatikana kutoka:

KRKA d.d.

ATC kanuni:

R03DA04

INN (Jina la Kimataifa):

theophylline

Kipimo:

200mg

Dawa fomu:

capsules modified-release

Vitengo katika mfuko:

(40/4x10/) in blister

Dawa ya aina:

Prescription

Idhini hali ya:

Registered

Idhini ya tarehe:

2017-04-03

Taarifa za kipeperushi

91 /263
SPC,
Labelin
lIine
1.3.1
YTBEP)K.nEHA
npRKa30M
npe,[(ce,[(aTeJUI
KOMRTeTa
KOHTPOJIli
Me,[(RUHHcKOH
R
cpapMaueBTIi"leCKOH
,[(ellTeJIbHOCTIi
MIiHlicTepcTBa
3,[(paBooxpaHeHli1i
Ii
COUHaJIbHOrO pa3BIiTlili
Pecny6JIliKIi
Ka3axCTaH
OT «24»
06
2015
r.
_N!?468_
HHCTPYKUHH no Me.llHUHHCKOMY npHMeHeHHIO
JleKapCTBeHHoro
Cpe.llCTBa
TEOTAP,L{
ToprOBoe
Ha3BaHHe
TeoTap'[(
MelK.!lYHapO.llHOe
HenaTeHTOBaHHoe
Ha3BaHHe
HeT
JIeKapcTBeHHaH
cpopMa
KancYJIbl
C MO'[(HCPI1URpOBaHHblM BblcBo6o)f()leHHeM
200
Mr
HJIH 350
Mr
COCTaB:
O'[(Ha
KancYJIa
cO)lep)!(IiT
_aKmU6Hoe 6ezqecm60 -_
Teo

Soma hati kamili

Tabia za bidhaa

1.3.1
Theophylline
SPC, Labeling and Package Leaflet
SmPCPIL153842_1
25.08.2020 – Updated: 25.08.2020
Page 1 of 8
1.
NAME OF THE MEDICINAL PRODUCT
Teotard 200 mg modified-release capsules
Teotard 350 mg modified-release capsules
2.
QUALITATIVE AND QUANTITATIVE COMPOSITION
Each modified-release capsule contains 200 mg or 350 mg theophylline.
For excipients, see 6.1.
3.
PHARMACEUTICAL FORM
Modified-release capsules.
Teotard modified-release capsules 200 mg:
The capsule body is transparent and green, the cap is non-transparent
and green; the capsules contain
white pellets.
Teotard modified-release capsules 350 mg:
The capsule body is transparent and green, the cap is non-transparent
and green; the capsules contain
white pellets.
4.
CLINICAL PARTICULARS
4.1
THERAPEUTIC INDICATIONS
All types of asthma, chronic obstructive bronchitis, pulmonary
emphysema, pulmonary hypertension
in chronic cor pulmonale, centrally induced respiratory disorders
during sleep.
4.2
POSOLOGY AND METHOD OF ADMINISTRATION
Dosage must be adjusted according to the patient’s age, body mass
and individual and individual
metabolic requirements and is therefore always determined by a doctor.
The size of the dose is
determined according to the patient’s ideal body weight, as
theophylline is not distributed into adipose
tissues.
The usual dose for adults weighing more than 40 kg is 350 mg
theophylline twice daily and for
very thin adults 200 mg theophylline twice daily.
Patients with nocturnal asthma or respiratory disorders during sleep
can take one dose of Teotard
daily, at bedtime. On average, 400 to 700 mg theophylline is
sufficient. Smokers may take unequal
doses, i.e. a higher dose in the evening and a lower dose in the
morning.
The therapeutic effect and tolerability of theophylline are evaluated
on the third day of treatment. If
the therapeutic effect is good, treatment is continued with the same
dose. If not, the dose should be
increased. If undesirable effects occur, the dose should be reduced or
treatment discontinued.
The dose of the